"The U.S. Food and Drug Administration today approved a device to help reduce the frequency of seizures in epilepsy patients who have not responded well to medications.
The RNS Stimulator consists of a small neurostimulator implanted within "...
Mysoline (primidone) , used alone or concomitantly with other anticonvulsants, is indicated in the control of grand mal, psychomotor, and focal epileptic seizures. It may control grand mal seizures refractory to other anticonvulsant therapy.
DOSAGE AND ADMINISTRATION
Patients 8 years of age and older who have received no previous treatment may be started on Mysoline (primidone) according to the following regimen using either 50 mg or scored 250 mg Mysoline (primidone) tablets:
Days 1 to 3: 100 to 125 mg at bedtime.
Days 4 to 6: 100 to 125 mg b.i.d.
Days 7 to 9: 100 to 125 mg t.i.d.
Day 10 to maintenance: 250 mg t.i.d.
For most adults and children 8 years of age and over, the usual maintenance dosage is three to four 250 mg Mysoline (primidone) tablets in divided doses (250 mg t.i.d. or q.i.d.). If required, an increase to five or six 250 mg tablets daily may be made but daily doses should not exceed 500 mg q.i.d.
INITIAL: ADULTS AND CHILDREN OVER 8
KEY: • = 50 mg tablet; • = 250 mg tablet
|AM||··||··||··||•||Adjust to Maintenance|
Dosage should be individualized to provide maximum benefit. In some cases, serum blood level determinations of primidone may be necessary for optimal dosage adjustment. The clinically effective serum level for primidone is between 5 to 12µg/mL.
In Patients Already Receiving Other Anticonvulsants
Mysoline (primidone) should be started at 100 to 125 mg at bedtime and gradually increased to maintenance level as the other drug is gradually decreased. This regimen should be continued until satisfactory dosage level is achieved for the combination, or the other medication is completely withdrawn. When therapy with Mysoline (primidone) alone is the objective, the transition from concomitant therapy should not be completed in less than two weeks.
For children under 8 years of age, the following regimen may be used:
Days 1 to 3: 50 mg at bedtime.
Days 4 to 6: 50 mg b.i.d.
Days 7 to 9: 100mg b.i.d.
Day 10 to maintenance: 125 mg t.i.d. to 250 mg t.i.d.
For children under 8 years of age, the usual maintenance dosage is 125 to 250 mg three times daily or, 10 to 25 mg/kg/day in divided doses.
Mysoline (primidone) Tablets
Each square-shaped, scored, yellow tablet, identified by "MYSOLINE (primidone) 250" and an embossed M, contains 250 mg of primidone, in bottles of 100 (NDC 66490-691-10)
Each square-shaped, scored, white tablet, identified by "MYSOLINE (primidone) 50" and an embossed M, contains 50 mg of primidone, in bottles of 100 (NDC 66490-690-10)
The appearance of these tablets is a trademark of Valeant Pharmaceuticals North America.
Store at 20°C-25°C (68°F-77°F). [See USP controlled room temperature].
Dispense in a tight, light-resistant container with a child-resistant closure.
Manufacture by: Piramal Healthcare Ltd. Plot No. 67-70, Sector - 2, Pithampur, 454775, Dist. Dhar, Madhya Pradesh, INDIA. Distributed by: Valeant Pharmaceuticals North America One Enterprise Aliso Viejo, CA 92656 U.S.A. Rev. 05/09.
Last reviewed on RxList: 8/12/2010
This monograph has been modified to include the generic and brand name in many instances.
Additional Mysoline Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find tips and treatments to control seizures.